Physician profile
Robert J Madden
NPI 1023224151
$605.71
in general payments reported to CMS, 2019-2025
15 companies · $33.04 in 2025
The $33.04 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.97 · 2020: $120 · 2021: $176 · 2022: $52.24 · 2023: $168 · 2025: $33.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $164.52 | 2020-2025 | |
| Amgen INC. | $125.54 | 2020-2023 | Repatha |
| Exact Sciences Corporation | $46.85 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $40.11 | 2020-2021 | |
| Abbvie INC. | $35.80 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $30.40 | 2021 | |
| Alkermes, INC. | $23.80 | 2019 | |
| Clarus Therapeutics INC. | $21.76 | 2021 | |
| Amarin Pharma, INC. | $20.58 | 2019 | |
| Athena Bioscience, LLC | $18.33 | 2023 | Qdolo |
| Qiagen, LLC | $17.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.64 | 2021 | |
| Lilly USA, LLC | $16.91 | 2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.02 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Madden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.